For the first time, the AMNOG seriously tackles the price monopoly of 1 January onwards for eligible new pharmaceuticals launched on. Since its introduction on January 1, , AMNOG has hampered the market access of some products in Germany such as Trajenta (anti-diabetic) and Retigabin. AMNOG is here to stay. However, all this changed at the beginning of AMNOG, meanwhile, sought to achieve a longer-term reduction of drug prices.
|Published (Last):||6 March 2013|
|PDF File Size:||3.2 Mb|
|ePub File Size:||12.66 Mb|
|Price:||Free* [*Free Regsitration Required]|
SinceICH E9 has been the primary reference for statistical principles governing clinical trials in support of marketing applications in Europe, Japan, and the United States.
Process of early benefit assessment at the G-BA. Biometrical Journal this issue. Whilst the early benefit evaluation in accordance with section 35a of Book Five of the Social Code is a differentiated finding as to the probability and extent of the benefit in comparison to the expedient comparative therapy, the focus of the evaluation in the fixed-rate arrangement is different.
There needs to be an explanation of the roles of secondary endpoints in interpreting trial results. If an additional benefit is proven to exist, the National Association of Statutory Health Insurance Funds negotiates with the pharmaceutical company a supplement on top of the price of the expedient comparative therapy.
Proof highest certainty of conclusions: In four sections, it defines in detail the steps of the benefit assessment. On the occasions when PFS is accepted as the primary endpoint, marketing authorization is typically conditioned on the new treatment not decreasing the OS when compared with the control in the study. Added benefit on severe symptoms and quality of life is perceived to have less value compared to that of survival. Authentic innovations which constitute real progress for patient care will increase.
What essential criteria are clarified in advance of the individual refund rate negotiations? The Board will determine the product price and the price will apply retroactively.
AMNOG – evaluation of new pharmaceutical – GKV-Spitzenverband
For the first time, the AMNOG seriously tackles the price monopoly of the pharmaceutical industry in Germany with this central arrangement. Prior to this, the amnlg in question may make a statement in a written and oral statement procedure.
Instead of using ICER, the German and French decision makers for pharmaceutical product reimbursement place their primary focus on determining amng clinical benefit from clinical studies. If several alternatives for the expedient comparative therapy are identified, the ajnog rate may not lead to higher annual therapy costs than those of the most economical alternative. Within three months of market authorization of a new pharmaceutical, the G-BA assesses recognition of any additional benefit claimed over the appropriate comparator.
What is meant by expedient comparative therapy, and why is it important?
Implementation of AMNOG: An industry perspective
Both statutory and private health insurers can presume in future that high refund rates are indeed countered by a corresponding additional benefit for patient care, and that they do not have to finance spurious innovations which all too frequently are excessively expensive, as they used to have to.
In the case of drugs for rare diseases orphan drugsthe approval of the drug is at the same time deemed to be proof of added benefit. British Medical Journal A medicinal product which wishes to distinguish itself from the expedient comparative therapy must exceed the benefit of this therapy, that is it must have an additional benefit in the stated categories. The refund rates negotiated for health insurance funds in Germany apply from the 13th month after the initial market launch.
Negotiation of reimbursement rates led to savings in amount of Mio. The benefit of a medicinal product is understood to mean its therapeutic effect as relevant to patients.
A methodological approach to determine minor, considerable and major treatment effets in the early benefit assessment of new drugs.
AMNOG since 2011
In this context the Institute must amnig only determine the probability, but also the extent of added benefit. We encourage pharmaceutical companies to seek early advice, which may lead to modifications to the development program. Value in Health 15A These statutory stipulations are complied with by the Federal Joint Committee by submitting a separate dossier for medicinal products that are comparable with fixed-rate medicinal products in pharmacological and ammnog terms Annex VI to the 5th Chapter of the Rules of Procedure of the Federal Joint Committee.
We discuss these issues from an industry perspective. Such medicinal products will have to put up with being in the second or third row in future — including when it comes to price. If it is not possible to prove any additional benefit in comparison to the comparative therapy previously identified by the Committee existing standard therapythe pharmaceutical is allocated to a reference price group with comparable active ingredients. This applies to every newly approved drug from 1 January The result of the examination, and the resolution of the Federal Joint Committee based on it, then act as a barrier: It is however also possible to compare with non-treatment.
Implementation of AMNOG: An industry perspective
This amount then applies to all persons with statutory insurance, as well as to those with private insurance. All pharmaceutical companies can do this within four weeks of the publication of the resolution of the Federal Joint Committee. It is only for those medicinal products that pharmaceutical companies can expect to receive an adequate refund rate in future.
In Octoberone year after publication of the first early benefit assessment, IQWiG staff members published an analysis of the dossier assessments completed among to the end of June The still relatively new law applies to all pharmaceutical products with a new wmnog ingredient that have been launched beginning January 1, If a treatment effect is found to be statistically significant at the prespecified significance level, the treatment is said to be efficacious.
Published online Sep 1. We understand products to be innovative which tangibly improve patient care.
We propose alternative approaches to address the requirements in some cases and invite other researchers to aamnog develop solutions in other cases. However, due to the brief processing period of 3 months, the involvement of patients is not easy. It would be an exaggeration to portray this withdrawal of the pharmaceutical companies as a risk that Germany might no longer be supplied with modern medicinal products. The situation is especially problematic when there is only one large registration trial.
In particular it contains statements on the extent of additional benefit, patient groups eligible for treatment, requirements for quality-assured administration, and the cost of treatment with the pharmaceutical. All English translations are courtesy translations only. We believe this is one area where we especially need our academic colleagues to join in and conduct research to provide more insight into the choice of the comparative measure, thresholds to define ammnog categories, one study against two studies, and how decisions on these issues will impact the design and analysis of registration trials.
European Journal of Cancer 45— Safety endpoints such as adverse events may also be relevant.